Novel micro-RNA therapeutic hits early targets in ischemic heart diseases
Earlier this year, Horizon announced a new collaboration and license agreement with Mammoth Biosciences.
Read More
Tag: Horizon
Horizon enlists Mammoth in CRISPR move
The San Fransisco-based biotech built the first CRISPR-based detection platform for diagnostics.
Read More
Horizon’s teprotumumab hits major R&D milestone
Horizon Pharma has announced positive Phase III clinical trial data for teprotumumab, as a treatment for active thyroid eye disease (TED).
Read More
Horizon and Rutgers Uni form gene editing partnership
Horizon Discovery and Rutgers University signed a partnership deal to commercialise a new gene editing technology.
Read More
Horizon completes enrollment in TED trial early
Horizon Pharma says it has completed enrollment in a confirmatory Phase III trial of teprotumumab in patients living with moderate-to-severe active thyroid eye disease (TED) ahead of schedule.
Read More
Clinigen buys global rights to Horizon’s Imukin
The UK’s Clinigen Group has bought global rights to rare disease therapy Imukin from Horizon Pharma, for an undisclosed amount.
Read More
Horizon hit by Actimimmune fail in Friedrich’s ataxia
Horizon Pharma shares dropped 20 percent after the company pulled the plug a late-stage trial testing Actimmune as a potential therapy Friedreich’s ataxia.
Read More
Horizon seals $800m Raptor buy
Dublin, Ireland-headquartered Horizon Pharma has now completed the acquisition of US group Raptor Pharmaceutical.
Read More
- GSK wins US approval for ROS1 lung cancer therapy
- Lundbeck secures FDA Fast Track for narcolepsy drug
- R1 Therapeutics begins global phase 2b trial of AP306 for hyperphosphatemia
- Mission Therapeutics divests MTX652 to Dimerix in deal worth up to $292 million
- Nouscom to present re‑treatment data in Lynch Syndrome at ESMO 2026
